IL4R and chronic obstructive pulmonary disease: The potential functions of eosinophils in COPD have remained unclear, and clinical trials have given inconsistent results.15–17 Clinical trials of IL-4R mAb (dupilumab, NCT04456673) and thymic stromal lymphopoietin mAb (tezepelumab, NCT05507242) are still ongoing.